Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Up 6.9% in March

Kazia Therapeutics Limited (NASDAQ:KZIA) saw a significant increase in short interest in March. As of March 31st, there was short interest totalling 259,500 shares, an increase of 6.9% from the March 15th total of 242,800 shares. Based on an average daily volume of 838,400 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Investors Weigh In On Kazia Therapeutics

A number of hedge funds have recently bought and sold shares of KZIA. Armistice Capital LLC purchased a new stake in Kazia Therapeutics during the fourth quarter valued at $1,088,000. Platinum Investment Management Ltd. purchased a new stake in Kazia Therapeutics during the fourth quarter valued at $801,000. Hsbc Holdings PLC purchased a new stake in Kazia Therapeutics during the fourth quarter valued at $45,000. Finally, Morgan Stanley raised its stake in Kazia Therapeutics by 25.9% during the fourth quarter. Morgan Stanley now owns 257,341 shares of the company’s stock valued at $158,000 after purchasing an additional 52,891 shares in the last quarter. Hedge funds and other institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Stock Up 17.9 %

Kazia Therapeutics stock opened at $0.34 on Thursday. The firm’s fifty day moving average is $0.29 and its 200 day moving average is $0.44. Kazia Therapeutics has a 52-week low of $0.19 and a 52-week high of $1.68.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.